• Latest Posts

Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth

PerkinElmer’s Horizon Discovery: the lowdown on base editing

The challenges of translating CRISPR to the clinic

CRISPR/Cas9: Challenges and outlook from an investor’s perspective

More News! 14 Oct 2022

ChristianaCare spins out new gene-editing company CorriXR Therapeutics

Growing hub Lithuania ready to welcome biotech sector to EFIB’22

ADVERTISEMENT
More News! 29 Sep 2022

Removing binding sites for an oncogene can slow cancer cell growth, researchers say

Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies

Scope Biosciences and WUR to improve CRISPR-Cas technology with new funds

CRISPR/CAS9 strategic alliance between Sigma-Aldrich and genOway expanded

Beyond Biotech podcast 11: Ilya Pharma, IRB Barcelona, Krystal Biotech, Phase Genomics

Gene therapies for lung cancer identified by international team of scientists

ADVERTISEMENT